We have screened the anti-AD and anti-diabetic drugs (either already marketed or in clinical trials) against their ability to bind to and inhibit the LPAR receptor activity, the SPIKE protein, and interfere with LPAR-SPIKE protein interaction. The gene discussed is CHMP5; the disease is Alzheimer disease.